{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:42:44Z","timestamp":1790646164370,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":538,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016875","name":"Chimerix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT 1161521"],"award-info":[{"award-number":["GNT 1161521"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jtct.2021.09.010","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T12:31:30Z","timestamp":1632227490000},"page":"957-967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8692-4145","authenticated-orcid":false,"given":"Michelle K.","family":"Yong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1322-9555","authenticated-orcid":false,"given":"Terri Lynn","family":"Shigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yae-Jean","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-3088","authenticated-orcid":false,"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtct.2021.09.010_bib0001","doi-asserted-by":"crossref","first-page":"e13187","DOI":"10.1111\/tid.13187","article-title":"Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl. Infect. Dis."},{"issue":"25","key":"10.1016\/j.jtct.2021.09.010_bib0002","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtct.2021.09.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era","author":"Sassine","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.jtct.2021.09.010_bib0004","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0006","doi-asserted-by":"crossref","first-page":"e12881","DOI":"10.1111\/tid.12881","article-title":"Cytomegalovirus resistance in CD34(+) -selected hematopoietic cell transplant recipients","volume":"20","author":"Kim","year":"2018","journal-title":"Transpl. Infect. Dis."},{"issue":"8","key":"10.1016\/j.jtct.2021.09.010_bib0007","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/infdis\/jiz298","article-title":"Compartmentalization of a multidrug-resistant cytomegalovirus UL54 mutant in a stem cell transplant recipient with encephalitis","volume":"220","author":"Piret","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.jtct.2021.09.010_bib0008","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/bmt.2010.35","article-title":"CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency","volume":"45","author":"Reddy","year":"2010","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0009","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1034\/j.1399-3062.2002.02005.x","article-title":"Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient","volume":"4","author":"Julin","year":"2002","journal-title":"Transpl. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcv.2013.01.003","article-title":"Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation","volume":"57","author":"Gohring","year":"2013","journal-title":"J. Clin. Virol."},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0011","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.V97.4.867","article-title":"Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes","volume":"97","author":"Nichols","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0012","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1399-3062.2007.00235.x","article-title":"Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Almyroudis","year":"2007","journal-title":"Transpl. Infect. Dis."},{"issue":"12","key":"10.1016\/j.jtct.2021.09.010_bib0013","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cmi.2015.06.009","volume":"21","author":"Liu","year":"2015","journal-title":"Clin. Microbiol. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0014","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkn521","article-title":"Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus","volume":"63","author":"Allice","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.jtct.2021.09.010_bib0015","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1128\/AAC.45.12.3669-3671.2001","article-title":"Lack of Emergence of Cytomegalovirus UL97 Mutations Conferring Ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients","volume":"45","author":"Gilbert","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"23","key":"10.1016\/j.jtct.2021.09.010_bib0016","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0017","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.jtct.2021.09.010_bib0018","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2017.07.025","article-title":"Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring","volume":"23","author":"Yong","year":"2017","journal-title":"Biol. Blood Marrow Transplant: J. Am. Soc. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0019","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/infdis\/163.4.716","article-title":"Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection","volume":"163","author":"Drew","year":"1991","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/jpids\/pit048","article-title":"Ganciclovir, Foscarnet, and Cidofovir: Antiviral drugs not just for cytomegalovirus","volume":"2","author":"Upadhyayula","year":"2013","journal-title":"J. Pediatric Infect. Dis. Soc."},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2021.09.010_bib0021","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1093\/ofid\/ofy210.1389","article-title":"Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant","volume":"5","author":"Artau","year":"2018","journal-title":"Open Forum Infect. Dis."},{"issue":"10","key":"10.1016\/j.jtct.2021.09.010_bib0022","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in Transplant recipients treated with Foscarnet for Ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2021.09.010_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jtct.2021.09.010_bib0024","unstructured":"Viracor E. CMV resistance: Ganciclovir, Foscarnet, Cidofovir. Available at: https:\/\/www.eurofins-viracor.com\/clinical\/test-menu\/5600-cmv-resistance-ganciclovir-foscarnet-cidofovir\/."},{"issue":"12","key":"10.1016\/j.jtct.2021.09.010_bib0025","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1128\/JCM.02411-13","article-title":"Temporal and spatial compartmentalization of drug-resistant cytomegalovirus (CMV) in a child with CMV meningoencephalitis: implications for sampling in molecular diagnosis","volume":"51","author":"Frange","year":"2013","journal-title":"J. Clin. Microbiol."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0026","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2012.07.006","article-title":"Cytomegalovirus ventriculoencephalitis with compartmentalization of antiviral-resistant cytomegalovirus in a T cell-depleted haploidentical peripheral blood stem cell transplant recipient","volume":"74","author":"Jeong","year":"2012","journal-title":"Diagnostic microbiology and infectious disease"},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0027","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1086\/499366","article-title":"Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient","volume":"42","author":"Miller","year":"2006","journal-title":"Clinical Infect. Dis."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0028","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12879-019-4016-1","article-title":"Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient","volume":"19","author":"Jung","year":"2019","journal-title":"BMC Infect. Dis."},{"issue":"10","key":"10.1016\/j.jtct.2021.09.010_bib0029","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/infdis\/jix048","article-title":"Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV Pneumonia","volume":"215","author":"Boeckh","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of Cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clinical Infect. Dis."},{"issue":"23","key":"10.1016\/j.jtct.2021.09.010_bib0031","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0032","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/QCO.0000000000000170","article-title":"Approach to drug-resistant cytomegalovirus in transplant recipients","volume":"28","author":"Chou","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.jtct.2021.09.010_bib0033","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1034\/j.1600-0609.2000.065005337.x","article-title":"Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients","volume":"65","author":"Dubreuil-Lemaire","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jtct.2021.09.010_bib0034","series-title":"ASTCT 2021 Meeting","article-title":"A Phase 3 Randomized Study of maribavir verus investigator-assigned antiviral therapy for the treatment of refractory\/resistant CMV infection in hematopoietic cell transplant or solid organ transplant recipients","author":"Marty","year":"2021"},{"issue":"24","key":"10.1016\/j.jtct.2021.09.010_bib0035","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0036","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jpids\/piz050","article-title":"Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient","volume":"9","author":"Kilgore","year":"2020","journal-title":"J. Pediatric. Infect. Dis. Soc."},{"key":"10.1016\/j.jtct.2021.09.010_bib0037","doi-asserted-by":"crossref","first-page":"e13687","DOI":"10.1111\/tid.13687","article-title":"Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients","author":"Linder","year":"2021","journal-title":"Transpl. Infect. Dis."},{"issue":"6","key":"10.1016\/j.jtct.2021.09.010_bib0038","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41409-018-0389-9","article-title":"Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis","volume":"54","author":"Knoll","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"10.1016\/j.jtct.2021.09.010_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00922-18","article-title":"New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.jtct.2021.09.010_bib0040","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/infdis\/jiz577","article-title":"Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients","volume":"221","author":"Douglas","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0041","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.001","article-title":"In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation","volume":"11","author":"Frietsch","year":"2019","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.jtct.2021.09.010_bib0042","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/1471-2334-13-330","article-title":"Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient","volume":"13","author":"Schubert","year":"2013","journal-title":"BMC Infect. Dis."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0043","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00007890-199608150-00013","article-title":"Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation","volume":"62","author":"Bacigalupo","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2021.09.010_bib0044","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jns.2018.02.029","article-title":"Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature","volume":"388","author":"Baghban","year":"2018","journal-title":"J. Neurol Sci."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0045","doi-asserted-by":"crossref","first-page":"e13267","DOI":"10.1111\/tid.13267","article-title":"Infections after kidney transplantation: A comparison of mTOR-Is and CNIs as basic immunosuppressants. A systematic review and meta-analysis","volume":"22","author":"Wolf","year":"2020","journal-title":"Transpl. Infect. Dis."},{"issue":"8","key":"10.1016\/j.jtct.2021.09.010_bib0046","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"issue":"7","key":"10.1016\/j.jtct.2021.09.010_bib0047","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1111\/j.1432-2277.2012.01489.x","article-title":"Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors","volume":"25","author":"Sab\u00e9","year":"2012","journal-title":"Transpl. Int.: Off. J. Eur. Soc. Organ Transplant."},{"issue":"5","key":"10.1016\/j.jtct.2021.09.010_bib0048","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1399-0012.2007.00699.x","article-title":"The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients","volume":"21","author":"Ozaki","year":"2007","journal-title":"Clin. Transplant."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0049","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-97-1-11","article-title":"Cytomegalovirus immune plasma in bone marrow transplant recipients","volume":"97","author":"Winston","year":"1982","journal-title":"Ann. Int. Med."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/civ215","article-title":"Reduced Mortality of Cytomegalovirus Pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices","volume":"61","author":"Erard","year":"2015","journal-title":"Clinical Infect. Dis."},{"issue":"5","key":"10.1016\/j.jtct.2021.09.010_bib0051","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","article-title":"Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis","volume":"27","author":"Raanani","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jtct.2021.09.010_bib0052","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1701113","volume":"21","author":"Ljungman","year":"1998","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.jtct.2021.09.010_bib0053","first-page":"132","article-title":"A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT)","volume":"83","author":"Zikos","year":"1998","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jtct.2021.09.010_bib0054","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41409-018-0166-9","article-title":"Cytotect\u00aeCP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study","volume":"53","author":"Alsuliman","year":"2018","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2005.01152.x","article-title":"Concurrent antiviral and immunosuppressive activities of leflunomide in vivo","volume":"6","author":"Chong","year":"2006","journal-title":"Am. J. Transplant.: Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"issue":"6","key":"10.1016\/j.jtct.2021.09.010_bib0056","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00007890-199909270-00014","article-title":"Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide","volume":"68","author":"Waldman","year":"1999","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0057","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/TP.0b013e3181e94106","article-title":"Utility of leflunomide in the treatment of complex cytomegalovirus syndromes","volume":"90","author":"Avery","year":"2010","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0058","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-2006-933412","article-title":"Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide","volume":"218","author":"Ehlert","year":"2006","journal-title":"Klin. Padiatr."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0059","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1399-3062.2006.00170.x","article-title":"Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation","volume":"9","author":"Battiwalla","year":"2007","journal-title":"Transpl. Infect. Dis."},{"issue":"12","key":"10.1016\/j.jtct.2021.09.010_bib0060","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.bmt.1704694","article-title":"Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection","volume":"34","author":"Avery","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jtct.2021.09.010_bib0061","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2016.08.027","article-title":"Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series","volume":"135","author":"El Chaer","year":"2016","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.jtct.2021.09.010_bib0062","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.bbmt.2019.04.028","article-title":"Use of Leflunomide for treatment of Cytomegalovirus infection in recipients of allogeneic stem cell transplant","volume":"25","author":"Gokarn","year":"2019","journal-title":"Biol. Blood Marrow Transplant: J. Am. Soc. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.jtct.2021.09.010_bib0063","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/tid.12435","article-title":"Combination therapy for multidrug-resistant cytomegalovirus disease","volume":"17","author":"Stuehler","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.jtct.2021.09.010_bib0064","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2019.01.008","article-title":"In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review","volume":"163","author":"Chemaly","year":"2019","journal-title":"Antivir. Res."},{"issue":"9","key":"10.1016\/j.jtct.2021.09.010_bib0065","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1086\/587106","article-title":"Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"46","author":"Shapira","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jtct.2021.09.010_bib0066","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/cid\/ciq050","article-title":"Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection","volume":"52","author":"Lau","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0067","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.antiviral.2011.03.184","article-title":"Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation","volume":"90","author":"Wolf","year":"2011","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.jtct.2021.09.010_bib0068","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/infdis\/jix192","article-title":"Identifying Cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation","volume":"215","author":"Yong","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.jtct.2021.09.010_bib0069","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of Cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the french compassionate program","volume":"26","author":"Robin","year":"2020","journal-title":"Biol. Blood Marrow Transplant: J Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.jtct.2021.09.010_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104647","article-title":"Characterization of the dynamics of human cytomegalovirus resistance to antiviral drugs by ultra-deep sequencing","volume":"173","author":"Guermouche","year":"2020","journal-title":"Antivir. Res."},{"issue":"8","key":"10.1016\/j.jtct.2021.09.010_bib0071","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bbmt.2020.03.019","article-title":"Impact of Preemptive Therapy for Cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: a retrospective single-center cohort study","volume":"26","author":"Zavras","year":"2020","journal-title":"Biol. Blood Marrow Transplant: J Am. Soc. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0072","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1034\/j.1399-3062.2000.020104.x","article-title":"Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients","volume":"2","author":"Turgeon","year":"2000","journal-title":"Transpl. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jtct.2021.09.010_bib0073","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1469-0691.12222","article-title":"Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clinical microbiology and infection: the official publication of the European Society of","volume":"20","author":"Venton","year":"2014","journal-title":"Clin. Microbiol. Infect. Dis."},{"issue":"9","key":"10.1016\/j.jtct.2021.09.010_bib0074","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00277-004-0887-2","article-title":"Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and Bone Marrow Transplant","volume":"83","author":"Tomonari","year":"2004","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jtct.2021.09.010_bib0075","first-page":"1","article-title":"Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients - the role of therapeutic drug monitoring","author":"Ho","year":"2020","journal-title":"Expert Rev. Anti. Infect. Ther."},{"issue":"9","key":"10.1016\/j.jtct.2021.09.010_bib0076","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/jac\/dkab195","article-title":"Ganciclovir therapeutic drug monitoring in transplant recipients","volume":"76","author":"M\u00e4rtson","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.jtct.2021.09.010_bib0077","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.02953-14","article-title":"Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients","volume":"58","author":"Gimenez","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0078","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01855-18","article-title":"Relationship of Ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety","volume":"63","author":"Ritchie","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"26","key":"10.1016\/j.jtct.2021.09.010_bib0079","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2021.09.010_bib0080","first-page":"62","article-title":"The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation","volume":"3","author":"Barrett","year":"2015","journal-title":"Ann. Transl. Med."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0081","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/CJI.0b013e31824300a2","article-title":"Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections","volume":"35","author":"Bao","year":"2012","journal-title":"J. Immunother."},{"issue":"22","key":"10.1016\/j.jtct.2021.09.010_bib0082","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.V128.22.61.61","article-title":"Third Party CMV-Specific Cytotoxic T Cells for Treatment of Antiviral Resistant CMV Infection after Hematopoietic Stem Cell Transplant","volume":"128","author":"Prockop","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2021.09.010_bib0083","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.bbmt.2018.08.024","article-title":"Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program","volume":"24","author":"Withers","year":"2018","journal-title":"Biol. Blood Marrow Transplant: J Am. Soc. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.jtct.2021.09.010_bib0084","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections","volume":"51","author":"O'Reilly","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.jtct.2021.09.010_bib0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/CVI.00697-14","article-title":"Seroprevalence of cytomegalovirus among children 1 to 5 years of age in the United States from the National Health and Nutrition Examination Survey of 2011 to 2012","volume":"22","author":"Lanzieri","year":"2015","journal-title":"Clinl Vaccine Immunol: CVI"},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0086","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QCO.0000000000000174","article-title":"Cytomegalovirus in immunocompromised children","volume":"28","author":"Vora","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0087","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/eji.201243100","article-title":"Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies","volume":"43","author":"Ritter","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jtct.2021.09.010_bib0088","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1743-422X-9-304","article-title":"Kinetics of IgG antibody to cytomegalovirus (CMV) after birth and seroprevalence of anti-CMV IgG in Chinese children","volume":"9","author":"Chen","year":"2012","journal-title":"Virol. J."},{"issue":"19","key":"10.1016\/j.jtct.2021.09.010_bib0089","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJM198005083021908","article-title":"Breast milk and the risk of cytomegalovirus infection","volume":"302","author":"Stagno","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1542\/peds.72.3.295","article-title":"Cytomegalovirus infection of breast milk and transmission in infancy","volume":"72","author":"Dworsky","year":"1983","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.jtct.2021.09.010_bib0091","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10875-019-00671-y","article-title":"Survey of infection control precautions for patients with severe combined immune deficiency","volume":"39","author":"Dergousoff","year":"2019","journal-title":"J. Clin. Immunol."},{"issue":"8","key":"10.1016\/j.jtct.2021.09.010_bib0092","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.jaip.2019.05.041","article-title":"The role of breast-feeding in cytomegalovirus transmission and hematopoietic stem cell transplant outcomes in infants with severe combined immunodeficiency","volume":"7","author":"Kelty","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"8","key":"10.1016\/j.jtct.2021.09.010_bib0093","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/j.jaip.2019.08.028","article-title":"CMV-Seropositive Mothers of SCID: To Breastfeed or Not?","volume":"7","author":"Walter","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.jtct.2021.09.010_bib0094","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jtct.2021.09.010_bib0095","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1399-3062.2012.00760.x","article-title":"Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients","volume":"14","author":"Kim","year":"2012","journal-title":"Transpl. Infect. Dis."},{"issue":"10","key":"10.1016\/j.jtct.2021.09.010_bib0096","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transplant: J Am. Soc. Blood Marrow Transplant."},{"issue":"6","key":"10.1016\/j.jtct.2021.09.010_bib0097","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/tid.12311","article-title":"The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations","volume":"16","author":"Choi","year":"2014","journal-title":"Transpl. Infect. Dis."},{"issue":"11","key":"10.1016\/j.jtct.2021.09.010_bib0098","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.3324\/haematol.2016.149880","article-title":"Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide","volume":"101","author":"Goldsmith","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jtct.2021.09.010_bib0099","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.bbmt.2018.05.008","article-title":"A Modified Intensive strategy to prevent Cytomegalovirus disease in seropositive umbilical cord blood transplantation recipients","volume":"24","author":"Hill","year":"2018","journal-title":"Biol. Blood Marrow Transplant: J Am. Soc. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0101","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor t cells","volume":"67","author":"Park","year":"2018","journal-title":"Clinical Infect. Dis."},{"issue":"8","key":"10.1016\/j.jtct.2021.09.010_bib0102","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.jtct.2021.09.010_bib0103","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor t-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect. Dis."},{"issue":"6","key":"10.1016\/j.jtct.2021.09.010_bib0104","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/cid\/ciy1025","article-title":"Inflammatory and infectious syndromes associated with cancer immunotherapies","volume":"69","author":"Fishman","year":"2019","journal-title":"Clinical Infect. Dis."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.jtct.2021.09.010_bib0106","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2021.09.010_bib0107","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.09.010_bib0108","series-title":"Late CMV Infection Following Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients","author":"Hodowanec","year":"2018"},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0109","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2021.09.010_bib0110","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant Cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.jtct.2021.09.010_bib0111","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00717-19","article-title":"Phase Ib trial to evaluate the safety and pharmacokinetics of multiple ascending doses of Filociclovir (MBX-400, Cyclopropavir) in healthy volunteers","volume":"63","author":"Rouphael","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0112","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/AAC.44.3.688-692.2000","article-title":"A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates","volume":"44","author":"Landry","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.jtct.2021.09.010_bib0113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219701","article-title":"Improvement in detecting cytomegalovirus drug resistance mutations in solid organ transplant recipients with suspected resistance using next generation sequencing","volume":"14","author":"Lopez-Aladid","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jtct.2021.09.010_bib0114","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/infdis\/jix157","article-title":"Characterization of human Cytomegalovirus genome diversity in immunocompromised hosts by whole-genome sequencing directly from clinical specimens","volume":"215","author":"Hage","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jtct.2021.09.010_bib0115","unstructured":"Viracor E. CMV Resistance: Letermovir. Available at: https:\/\/www.eurofins-viracor.com\/clinical\/test-menu\/30722-cmv-resistance-letermovir\/."},{"issue":"4","key":"10.1016\/j.jtct.2021.09.010_bib0116","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"issue":"10","key":"10.1016\/j.jtct.2021.09.010_bib0117","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","volume":"31","author":"Neuenhahn","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jtct.2021.09.010_bib0118","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2021.09.010_bib0119","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T-cells for therapy-resistant disease","author":"Uhlin","year":"2012","journal-title":"Clinical Infect. Dis."},{"issue":"11","key":"10.1016\/j.jtct.2021.09.010_bib0120","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/bloodadvances.2019000121","article-title":"Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis","volume":"3","author":"Seo","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.jtct.2021.09.010_bib0121","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-6143.2009.02872.x","article-title":"Successful immunotherapy of HCMV disease using virus-specific T cells expanded from an allogeneic stem cell transplant recipient","volume":"10","author":"Hill","year":"2010","journal-title":"Am. J. Transplant.: Official J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"10.1016\/j.jtct.2021.09.010_bib0122","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2021.04.009","article-title":"Ocular outcomes after treatment of cytomegalovirus (CMV) retinitis using adoptive immunotherapy with CMV-specific cytotoxic T-lymphocytes","author":"Gupta","year":"2021","journal-title":"Ophthalmol. Retina"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721012525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721012525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:08:44Z","timestamp":1763003324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721012525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":122,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2666636721012525"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.09.010","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}